Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
$2.27
-3.0%
$2.15
$1.15
$33.98
$113.04M-2.05868,147 shs869,400 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-2.99%+0.89%+2.71%+1.34%-92.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2.3075 of 5 stars
1.01.00.04.72.10.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2.00
Hold$2.00-11.89% Downside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/A$3.03 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-$24.34M-$2.55N/AN/AN/AN/A-59.54%-50.16%N/A

Latest SAVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A-$0.18N/A-$0.92N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A
9.08
9.08

Institutional Ownership

CompanyInstitutional Ownership
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
38.05%

Insider Ownership

CompanyInsider Ownership
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
12.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
3048.31 million42.41 millionOptionable

Recent News About These Companies

Cassava Sciences Announces Positive Preclinical Results
Cassava Sciences Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cassava Sciences stock logo

Cassava Sciences NASDAQ:SAVA

$2.27 -0.07 (-2.99%)
Closing price 08/18/2025 04:00 PM Eastern
Extended Trading
$2.28 +0.01 (+0.44%)
As of 08/18/2025 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.